Profile
| Role | Director |
|---|---|
| Notability | 30/100 |
Board memberships
- Maze Therapeutics, Inc.
- BridgeBio Pharma, Inc.
Updated Jul 16, 2026
HOMCY CHARLES J has filed 4 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $13.91M.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | BBIO | BridgeBio Pharma, Inc. | A — Grant or award | 4.0K | $0.00 | |
| 2026-06-23 | BBIO | BridgeBio Pharma, Inc. | F — Tax withholding / forfeiture | 788 | $66.27 | $52K |
| 2026-05-06 | MAZE | Maze Therapeutics, Inc. | G — Bona-fide gift | 7.4K | $0.00 | |
| 2025-08-08 | BBIO | BridgeBio Pharma, Inc. | S — Open-market sale | 50.0K | $48.00 | $2.40M |
| 2025-08-08 | BBIO | BridgeBio Pharma, Inc. | S — Open-market sale | 58.3K | $46.64 | $2.72M |
| 2025-08-08 | BBIO | BridgeBio Pharma, Inc. | S — Open-market sale | 191.7K | $45.87 | $8.79M |
| 2025-06-27 | BBIO | BridgeBio Pharma, Inc. | G — Bona-fide gift | 20.0K | $0.00 | |
| 2025-06-20 | BBIO | BridgeBio Pharma, Inc. | A — Grant or award | 6.6K | $0.00 |
HOMCY CHARLES J is a corporate insider — currently tracked as Director of BridgeBio Pharma, Inc. (BBIO). InsiderAlpha tracks every SEC Form 4 filing in real time.
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($13.91M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live HOMCY CHARLES J profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.